Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) has been given an average recommendation of “Buy” by the six ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $3.35.
Several brokerages have recently commented on NVCN. Canaccord Genuity reissued a “buy” rating and issued a $1.05 price objective on shares of Neovasc Inc (US) in a research note on Friday. ValuEngine downgraded Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Finally, Zacks Investment Research downgraded Neovasc Inc (US) from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th.
Shares of Neovasc Inc (NASDAQ:NVCN) traded up $0.13 during trading on Friday, hitting $0.68. The stock had a trading volume of 6,468,660 shares, compared to its average volume of 615,783. The stock has a market capitalization of $55.77, a P/E ratio of 2.52 and a beta of 1.48. Neovasc Inc has a 12-month low of $0.50 and a 12-month high of $2.12.
Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) last issued its quarterly earnings data on Tuesday, November 14th. The medical equipment provider reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.04). Neovasc Inc (US) had a negative return on equity of 85.81% and a net margin of 268.35%. equities analysts forecast that Neovasc Inc will post -0.21 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Neovasc Inc (US) stock. Capital World Investors lifted its holdings in shares of Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) by 9.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,294,667 shares of the medical equipment provider’s stock after acquiring an additional 522,864 shares during the quarter. Capital World Investors owned 7.98% of Neovasc Inc (US) worth $8,737,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 19.04% of the company’s stock.
WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/analysts-set-neovasc-inc-us-nvcn-pt-at-4-50.html.
About Neovasc Inc (US)
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with MarketBeat.com's FREE daily email newsletter.